Skip to content

Volume of Perirenal Fat and Chronic Kidney Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02870621
Enrollment
12
Registered
2016-08-17
Start date
2012-07-31
Completion date
Unknown
Last updated
2016-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrectomy

Brief summary

The perirenal fat may alter renal function by secreting fibrotic inflammatory agents when accumulates during obesity. Nephrectomy for renal tumor is a model that would provide tissue samples to test this hypothesis. Renal tumor could itself be responsible for inflammation and fibrosis in its environment. This study aims to measure the influence of the tumor on his kidney Environment and fat and define molecular markers not influenced by renal tumor. The main objective is to compare the inflammation of the perirenal fat taken in two locations in the same patient, in contact and 4 cm from the outer edge of the tumor, each patient as his own control. The secondary objective is to compare the degree of interstitial fibrosis of the renal cortex in the same sampling methods.

Interventions

None listed

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or more * Indication nephrectomy for kidney tumor * Stadium T1a, T1b or T2 and M0 according to the TNM (Tumor Nodes Metastasis) classification of tumors

Exclusion criteria

* Nephrectomy indication for chronic pyelonephritis * Asian topic because of the difference threshold values used to characterize the metabolic syndrome in this population * Diabetes type I or II due to a high score of renal interstitial fibrosis * Infection with HIV (Human immunodeficiency virus) * Partial nephrectomy (a part of the kidney on the side of the tumor is left in place)

Design outcomes

Primary

MeasureTime frame
Numbers of renal interstitial fibrosis1 day

Countries

France

Contacts

Primary ContactGuillaume FAVRE, Dr
favre.g@chu-nice.fr4 92 03 88 24

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026